Evogene Other Stockholder Equity vs Current Deferred Revenue Analysis

EVGN Stock

USD 1.62 0.02 1.25%

Evogene financial indicator trend analysis is much more than just examining Evogene latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evogene is a good investment. Please check the relationship between Evogene Other Stockholder Equity and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Other Stockholder Equity vs Current Deferred Revenue

Other Stockholder Equity vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evogene Other Stockholder Equity account and Current Deferred Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Evogene's Other Stockholder Equity and Current Deferred Revenue is -0.94. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Evogene, assuming nothing else is changed. The correlation between historical values of Evogene's Other Stockholder Equity and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Evogene are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Stockholder Equity i.e., Evogene's Other Stockholder Equity and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Other Stockholder Equity

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Evogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.At this time, Evogene's Issuance Of Capital Stock is very stable compared to the past year. As of the 24th of November 2024, Sales General And Administrative To Revenue is likely to grow to 1.53, while Selling General Administrative is likely to drop about 5.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	1.4M	3.3M	171K	162.5K
Depreciation And Amortization	2.2M	2.6M	2.6M	2.8M

Interest Expense Depreciation And Amortization

Evogene fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		0.35	-0.48	0.09	0.95	-0.54	0.47	0.33	-0.2	0.6	0.67	-0.47	0.0	-0.33	0.69	0.67	-0.01	-0.39	0.53	-0.3	-0.31	0.97	0.54	-0.26	-0.57	-0.15
Common Stock Shares Outstanding	0.35		-0.3	-0.04	0.52	-0.48	0.34	-0.36	-0.15	0.69	0.38	-0.37	-0.15	-0.8	0.57	0.59	0.46	0.11	0.77	-0.65	-0.19	0.44	0.1	-0.78	-0.54	-0.63
Other Current Liab	-0.48	-0.3		0.53	-0.52	0.34	0.04	0.06	0.14	-0.5	-0.48	0.68	-0.28	0.17	-0.25	-0.22	0.19	-0.19	-0.18	0.48	0.2	-0.57	-0.11	0.17	0.39	-0.1
Total Current Liabilities	0.09	-0.04	0.53		0.06	0.02	0.46	0.32	0.0	-0.15	-0.16	0.54	-0.69	-0.25	0.37	0.39	0.65	-0.52	0.45	0.02	0.17	0.03	0.19	-0.24	0.06	-0.59
Total Stockholder Equity	0.95	0.52	-0.52	0.06		-0.72	0.42	0.19	-0.15	0.71	0.69	-0.56	0.03	-0.46	0.69	0.68	0.06	-0.32	0.66	-0.44	-0.32	0.95	0.44	-0.37	-0.64	-0.25
Other Liab	-0.54	-0.48	0.34	0.02	-0.72		0.11	-0.06	0.31	-0.47	-0.43	0.74	-0.31	0.42	-0.26	-0.27	0.12	0.19	-0.49	0.23	0.61	-0.53	-0.19	0.28	0.76	0.13
Accounts Payable	0.47	0.34	0.04	0.46	0.42	0.11		0.0	-0.05	0.44	0.29	0.26	-0.57	-0.28	0.7	0.7	0.61	-0.22	0.57	-0.37	0.21	0.47	0.41	-0.36	-0.07	-0.52
Cash	0.33	-0.36	0.06	0.32	0.19	-0.06	0.0		0.02	-0.54	-0.38	0.1	-0.3	0.19	-0.08	-0.09	-0.17	-0.92	-0.09	0.35	-0.01	0.23	0.3	0.23	0.06	0.16
Other Assets	-0.2	-0.15	0.14	0.0	-0.15	0.31	-0.05	0.02		-0.17	-0.14	0.56	-0.18	0.1	-0.03	-0.01	0.08	-0.02	-0.05	0.11	0.88	-0.23	-0.38	0.06	0.72	-0.01
Short Term Investments	0.6	0.69	-0.5	-0.15	0.71	-0.47	0.44	-0.54	-0.17		0.86	-0.5	0.16	-0.54	0.68	0.68	0.23	0.38	0.64	-0.69	-0.23	0.69	0.18	-0.51	-0.58	-0.36
Other Current Assets	0.67	0.38	-0.48	-0.16	0.69	-0.43	0.29	-0.38	-0.14	0.86		-0.48	0.42	-0.22	0.61	0.59	-0.09	0.36	0.36	-0.3	-0.28	0.68	0.33	-0.17	-0.44	-0.04
Total Liab	-0.47	-0.37	0.68	0.54	-0.56	0.74	0.26	0.1	0.56	-0.5	-0.48		-0.59	0.21	-0.05	-0.03	0.43	-0.15	-0.13	0.32	0.77	-0.53	-0.18	0.11	0.82	-0.21
Intangible Assets	0.0	-0.15	-0.28	-0.69	0.03	-0.31	-0.57	-0.3	-0.18	0.16	0.42	-0.59		0.44	-0.41	-0.42	-0.85	0.5	-0.52	0.3	-0.49	-0.04	0.0	0.54	-0.17	0.75
Common Stock	-0.33	-0.8	0.17	-0.25	-0.46	0.42	-0.28	0.19	0.1	-0.54	-0.22	0.21	0.44		-0.68	-0.7	-0.69	0.08	-0.89	0.67	0.08	-0.44	-0.03	0.98	0.56	0.87
Property Plant Equipment	0.69	0.57	-0.25	0.37	0.69	-0.26	0.7	-0.08	-0.03	0.68	0.61	-0.05	-0.41	-0.68		1.0	0.59	-0.12	0.82	-0.45	0.05	0.7	0.45	-0.69	-0.35	-0.7
Property Plant And Equipment Net	0.67	0.59	-0.22	0.39	0.68	-0.27	0.7	-0.09	-0.01	0.68	0.59	-0.03	-0.42	-0.7	1.0		0.61	-0.13	0.85	-0.46	0.07	0.69	0.43	-0.71	-0.34	-0.73
Current Deferred Revenue	-0.01	0.46	0.19	0.65	0.06	0.12	0.61	-0.17	0.08	0.23	-0.09	0.43	-0.85	-0.69	0.59	0.61		-0.12	0.74	-0.52	0.37	0.08	-0.06	-0.77	-0.03	-0.94
Net Debt	-0.39	0.11	-0.19	-0.52	-0.32	0.19	-0.22	-0.92	-0.02	0.38	0.36	-0.15	0.5	0.08	-0.12	-0.13	-0.12		-0.22	-0.18	0.0	-0.31	-0.31	0.04	0.06	0.15
Retained Earnings	0.53	0.77	-0.18	0.45	0.66	-0.49	0.57	-0.09	-0.05	0.64	0.36	-0.13	-0.52	-0.89	0.82	0.85	0.74	-0.22		-0.68	-0.02	0.6	0.21	-0.87	-0.5	-0.88
Non Current Assets Total	-0.3	-0.65	0.48	0.02	-0.44	0.23	-0.37	0.35	0.11	-0.69	-0.3	0.32	0.3	0.67	-0.45	-0.46	-0.52	-0.18	-0.68		-0.01	-0.5	0.08	0.69	0.49	0.58
Non Currrent Assets Other	-0.31	-0.19	0.2	0.17	-0.32	0.61	0.21	-0.01	0.88	-0.23	-0.28	0.77	-0.49	0.08	0.05	0.07	0.37	0.0	-0.02	-0.01		-0.3	-0.34	-0.04	0.79	-0.19
Cash And Short Term Investments	0.97	0.44	-0.57	0.03	0.95	-0.53	0.47	0.23	-0.23	0.69	0.68	-0.53	-0.04	-0.44	0.7	0.69	0.08	-0.31	0.6	-0.5	-0.3		0.46	-0.38	-0.63	-0.24
Net Receivables	0.54	0.1	-0.11	0.19	0.44	-0.19	0.41	0.3	-0.38	0.18	0.33	-0.18	0.0	-0.03	0.45	0.43	-0.06	-0.31	0.21	0.08	-0.34	0.46		0.01	-0.28	-0.04
Common Stock Total Equity	-0.26	-0.78	0.17	-0.24	-0.37	0.28	-0.36	0.23	0.06	-0.51	-0.17	0.11	0.54	0.98	-0.69	-0.71	-0.77	0.04	-0.87	0.69	-0.04	-0.38	0.01		0.45	0.91
Non Current Liabilities Total	-0.57	-0.54	0.39	0.06	-0.64	0.76	-0.07	0.06	0.72	-0.58	-0.44	0.82	-0.17	0.56	-0.35	-0.34	-0.03	0.06	-0.5	0.49	0.79	-0.63	-0.28	0.45		0.25
Other Stockholder Equity	-0.15	-0.63	-0.1	-0.59	-0.25	0.13	-0.52	0.16	-0.01	-0.36	-0.04	-0.21	0.75	0.87	-0.7	-0.73	-0.94	0.15	-0.88	0.58	-0.19	-0.24	-0.04	0.91	0.25

Click cells to compare fundamentals

Evogene Account Relationship Matchups

Evogene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	71.4M	71.9M	76.3M	56.1M	51.1M	65.0M
Common Stock Shares Outstanding	25.8M	2.8M	4.0M	4.1M	4.6M	4.3M
Other Current Liab	3.4M	8.0M	4.3M	3.6M	3.6M	2.8M
Total Current Liabilities	5.7M	9.7M	6.9M	5.6M	6.9M	5.6M
Total Stockholder Equity	50.1M	46.0M	54.0M	27.9M	12.1M	11.5M
Other Liab	3.3M	3.7M	4.3M	14.8M	17.0M	17.8M
Accounts Payable	1.0M	863K	1.5M	1.0M	1.8M	1.2M
Cash	34.7M	46.2M	32.3M	29.0M	20.8M	26.8M
Short Term Investments	12.1M	2M	21.5M	6.4M	10.3M	9.8M
Other Current Assets	894K	1.4M	1.7M	1.0M	(708K)	(672.6K)
Total Liab	11.1M	15.0M	12.9M	21.3M	18.0M	14.6M
Property Plant Equipment	5.3M	3.9M	4.2M	4.1M	3.7M	4.7M
Property Plant And Equipment Net	5.3M	3.9M	4.2M	4.1M	3.4M	4.5M
Current Deferred Revenue	423K	119K	264K	101K	750K	987.3K
Net Debt	(31.8M)	(43.8M)	(29.7M)	(17.1M)	(9.3M)	(9.7M)
Retained Earnings	(155.9M)	(179.3M)	(207.1M)	(233.7M)	(257.6M)	(244.7M)
Non Current Assets Total	22.3M	20.1M	19.4M	18.4M	16.6M	13.2M
Cash And Short Term Investments	46.9M	48.2M	53.9M	35.4M	31.1M	55.2M
Net Receivables	2.2M	2.2M	1.2M	803K	2.4M	1.5M
Liabilities And Stockholders Equity	71.4M	71.9M	76.3M	56.1M	51.1M	66.8M
Non Current Liabilities Total	5.4M	5.4M	6.0M	15.7M	11.0M	6.5M
Other Stockholder Equity	205.9M	225.1M	260.5M	261.4M	269.4M	225.1M
Property Plant And Equipment Gross	5.3M	3.9M	4.2M	4.1M	26.0M	27.3M
Total Current Assets	49.0M	51.8M	56.9M	37.8M	34.5M	57.2M
Accumulated Other Comprehensive Income	205.9M	225.1M	260.5M	261.4M	269.4M	282.8M
Short Term Debt	895K	777K	974K	1.8M	853K	1.7M
Net Tangible Assets	33.1M	29.9M	38.8M	13.8M	12.4M	11.8M
Inventory	(894K)	(1.4M)	92K	566K	1.7M	1.8M
Non Current Liabilities Other	3.4M	2.9M	3.3M	3.7M	4.2M	3.7M
Net Invested Capital	50.1M	46.0M	54.0M	38.0M	22.4M	37.7M
Net Working Capital	43.3M	42.1M	50.0M	32.1M	27.5M	35.8M

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

0.81	ME	23Andme Holding	Pair Corr
0.89	VALN	Valneva SE ADR	Pair Corr
0.74	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against Evogene Stock

0.59	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.49	RNXT	RenovoRx	Pair Corr
0.44	NXGLW	NexGel Warrant	Pair Corr
0.41	KZR	Kezar Life Sciences	Pair Corr
0.38	MLYS	Mineralys Therapeutics,	Pair Corr

The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.

The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:

How To Invest In Evogene

Details

Is Evogene Stock a good investment?

Details

What is Evogene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.84)

Revenue Per Share

1.881

Quarterly Revenue Growth

0.398

Return On Assets

(0.28)

Return On Equity

(0.82)

The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evogene Other Stockholder Equity vs Current Deferred Revenue Analysis

Other Stockholder Equity vs Current Deferred Revenue

Other Stockholder Equity vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Current Deferred Revenue

Evogene fundamental ratios Correlations

Evogene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evogene fundamental ratios Accounts

Pair Trading with Evogene

Moving together with Evogene Stock

Moving against Evogene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Property Plant Equipment
Common Stock Total Equity	+ 0.98	Common Stock
Cash And Short Term Investments	+ 0.97	Total Assets
Total Stockholder Equity	+ 0.95	Total Assets
Cash And Short Term Investments	+ 0.95	Total Stockholder Equity
Other Stockholder Equity	+ 0.91	Common Stock Total Equity

Other Stockholder Equity	- 0.94	Current Deferred Revenue
Net Debt	- 0.92	Cash
Retained Earnings	- 0.89	Common Stock
Other Stockholder Equity	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Current Deferred Revenue	- 0.85	Intangible Assets